Hap Trading, LLC Cel Sci Corp Call Options Transaction History

Hap Trading, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 12, 2022	SELL	$3.93 - $7.7 $61,308 - $120,120	-15,600 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$8.68 - $27.49 $868 - $2,749	-100 Reduced 0.64%	15,600 $32,000
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $1.66 Million - $2.5 Million	-150,300 Reduced 90.54%	15,700 $90,000
Q3 2020 Nov 13, 2020	SELL	$11.69 - $14.54 $2,338 - $2,908	-200 Reduced 0.12%	166,000 $170,000
Q2 2020 Aug 10, 2020	SELL	$9.75 - $17.6 $4,875 - $8,800	-500 Reduced 0.3%	166,200 $1.09 Million
Q1 2020 May 08, 2020	BUY	$7.54 - $17.05 $1.09 Million - $2.46 Million	144,100 Added 637.61%	166,700 $629,000
Q4 2019 Feb 11, 2020	SELL	$6.71 - $9.55 $6,039 - $8,595	-900 Reduced 3.83%	22,600 $70,000
Q3 2019 Nov 12, 2019	BUY	$6.0 - $9.6 $141,000 - $225,600	23,500 New	23,500 $87,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $33.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.